MARICELA. GUZMAN: Open Payments
NPI 1437811528 · EL CENTRO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$511 in 20 payments from 14 companies in 2025. Trend: 2023 $107 · 2024 $675 · 2025 $511
Food & beverage: $511
| Company | Payments | Amount |
|---|---|---|
| Eisai Inc. | 4 | $124 |
| Karyopharm Therapeutics Inc. | 3 | $96 |
| GlaxoSmithKline, LLC. | 2 | $46 |
| PharmaEssentia USA Corporation | 1 | $32 |
| TAIHO ONCOLOGY, INC. | 1 | $31 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| SOBI, INC | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Dendreon Pharmaceuticals LLC | 1 | $20 |
| Janssen Biotech, Inc. | 1 | $20 |
Products named: Lenvima, XPOVIO, OJJAARA, BESREMI, LONSURF, LIBTAYO, Vonjo, ORGOVYX.
Industry payments across CA — which companies pay providers there.
